Results 21 to 30 of about 9,938 (160)
Medicina, 2022 Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase.
Agnete Teivane +6 more
doaj +1 more source
Using alteplase nephrostomy tube installation for thrombolysis of ureter tract clot obstruction
Urology Case Reports, 2021 In literature, few cases have been reported regarding the use of alteplase installation in a nephrostomy as anticoagulant treatment of blood clots in the upper urinary tract.Our case -report provides a unique case of alteplase installation in the ...
Paoyan Lin +2 more
doaj +1 more source
Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h
Frontiers in Neurology, 2022 BackgroundThe efficacy and safety of intravenous alteplase administered 3–4.5 h after acute ischemic stroke have been demonstrated. However, whether responses differ between low-dose and standard-dose alteplase during this time window and whether certain
Chih-Hao Chen +18 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives Acute kidney injury (AKI) is a common but often underrecognized complication in ischemic stroke patients undergoing mechanical thrombectomy, particularly among those with pre‐existing renal impairment. This study evaluated the incidence, risk factors, and clinical impact of AKI in this high‐risk population.
Michał Borończyk +10 more
wiley +1 more source
Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseAlthough intravenous thrombolysis with alteplase remains the primary treatment for acute ischemic stroke, tenecteplase has shown potential advantages over alteplase.
Liyuan Wang +5 more
doaj +1 more source
The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt
Frontiers in Neurology, 2023 IntroductionStroke is the second leading cause of mortality worldwide. Five percent of all the disability-adjusted life years (DALYs) lost around the world are attributed to stroke. This study aimed to assess the economic burden of acute ischemic stroke (
Hany Aref +5 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Introduction/Objective Acute intracranial stenting during endovascular thrombectomy (EVT) for ischemic stroke requires intraprocedural antiplatelet therapy (APT) to maintain patency. However, the hemorrhagic risk of combining APT with intravenous thrombolysis (IVT) remains uncertain.
Aaron Rodriguez‐Calienes +75 more
wiley +1 more source
Argatroban plus alteplase in posterior versus anterior circulation stroke
Annals of Clinical and Translational NeurologyObjective ARAIS trial failed to demonstrate benefit of argatroban as an adjunct to alteplase for stroke. Given differences between anterior circulation stroke (ACS) and posterior circulation stroke (PCS), we performed prespecified secondary analysis to ...
Yu Cui, Hui‐Sheng Chen
doaj +1 more source
Thrombosis Update, 2021 Background: Swine have been used as a large animal translational research model to investigate the effectiveness of fibrinolytic agents. However, swine thrombi have different characteristics than human thrombi, which may confer more resistance to ...
Evandro M. Neto-Neves +2 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand +5 more
wiley +1 more source